url:https://finance.yahoo.com/m/5dc581a3-8733-3e86-b0c4-c52b90deb97b/crispr-therapeutics-rallies.html
title:Crispr_Therapeutics_Rallies_On_Bullish_Views_Of_FirstEver_GeneEditing_Drug
The FDA appears likely to approve Crispr's gene-editing approach to sickle cell disease, analysts said Wednesday as CRSP stock gapped higher.